drugset / Trial / NCT00835328
Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
RandomizedCrossoverOpen-labelTreatment
Summary
The primary aim of this study is to evaluate the effect of Exendin (9-39) on glucose requirements to maintain euglycemia in pediatric patients with congenital hyperinsulinism (CHI) who have failed medical therapy. The secondary aims are to determine the therapeutic plasma levels, plasma half-life and pharmacokinetics of Exendin (9-39) during a 9-hour intravenous infusion.
Timeline
- Start
- 2009-08-26
- Primary completion
- 2017-01-28
- Completion
- 2017-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avexitide | Peptide | 0.02 mg/kg | Intravenous |
| Subject | Avexitide | Peptide | 0.04 mg/kg | Intravenous |
| Subject | Avexitide | Peptide | 0.1 mg/kg | Intravenous |
| Subject | Avexitide | Peptide | 0.2 mg/kg | Intravenous |